OPKO Health, Inc. (0KCS.L)
USD 1.46
(-0.69%)
USD 1.46
(-0.69%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 863.49 Million USD | -14.01% |
| 2022 | 1 Billion USD | -43.42% |
| 2021 | 1.77 Billion USD | 23.64% |
| 2020 | 1.43 Billion USD | 59.15% |
| 2019 | 901.9 Million USD | -8.93% |
| 2018 | 990.3 Million USD | 2.51% |
| 2017 | 966 Million USD | -20.93% |
| 2016 | 1.22 Billion USD | 148.46% |
| 2015 | 491.7 Million USD | 439.74% |
| 2014 | 91.1 Million USD | -5.63% |
| 2013 | 96.53 Million USD | 105.19% |
| 2012 | 47.04 Million USD | 68.14% |
| 2011 | 27.97 Million USD | -1.81% |
| 2010 | 28.49 Million USD | 116.73% |
| 2009 | 13.14 Million USD | 39.27% |
| 2008 | 9.44 Million USD | 1014.52% |
| 2007 | 847 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 13 Thousand USD | -97.69% |
| 2002 | 562 Thousand USD | -57.84% |
| 2001 | 1.33 Million USD | 54.1% |
| 2000 | 865 Thousand USD | -37.09% |
| 1999 | 1.37 Million USD | 14.58% |
| 1998 | 1.2 Million USD | 1100.0% |
| 1997 | 100 Thousand USD | 0.0% |
| 1996 | 100 Thousand USD | 0.0% |
| 1995 | 100 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 173.68 Million USD | -4.52% |
| 2024 Q2 | 182.18 Million USD | 4.89% |
| 2023 Q1 | 237.6 Million USD | 28.16% |
| 2023 Q2 | 265.41 Million USD | 11.71% |
| 2023 Q3 | 178.6 Million USD | -32.71% |
| 2023 FY | 863.49 Million USD | -14.01% |
| 2023 Q4 | 181.9 Million USD | 1.85% |
| 2022 Q2 | 309.89 Million USD | -5.87% |
| 2022 Q1 | 329.21 Million USD | -17.96% |
| 2022 FY | 1 Billion USD | -43.42% |
| 2022 Q3 | 179.74 Million USD | -42.0% |
| 2022 Q4 | 185.4 Million USD | 3.15% |
| 2021 FY | 1.77 Billion USD | 23.64% |
| 2021 Q1 | 545.16 Million USD | 10.22% |
| 2021 Q4 | 401.3 Million USD | 4.01% |
| 2021 Q3 | 385.81 Million USD | -12.79% |
| 2021 Q2 | 442.4 Million USD | -18.85% |
| 2020 Q4 | 494.6 Million USD | 15.54% |
| 2020 Q1 | 211.46 Million USD | -5.72% |
| 2020 Q3 | 428.06 Million USD | 42.12% |
| 2020 FY | 1.43 Billion USD | 59.15% |
| 2020 Q2 | 301.2 Million USD | 42.44% |
| 2019 Q4 | 224.3 Million USD | -1.95% |
| 2019 Q1 | 222.5 Million USD | 0.27% |
| 2019 Q2 | 226.36 Million USD | 1.74% |
| 2019 Q3 | 228.77 Million USD | 1.06% |
| 2019 FY | 901.9 Million USD | -8.93% |
| 2018 Q3 | 249.81 Million USD | -5.26% |
| 2018 Q4 | 221.9 Million USD | -11.17% |
| 2018 Q1 | 254.9 Million USD | 31.6% |
| 2018 FY | 990.3 Million USD | 2.51% |
| 2018 Q2 | 263.68 Million USD | 3.45% |
| 2017 Q4 | 193.7 Million USD | -26.49% |
| 2017 Q3 | 263.49 Million USD | -16.14% |
| 2017 Q1 | 296.09 Million USD | 7.48% |
| 2017 Q2 | 314.21 Million USD | 6.12% |
| 2017 FY | 966 Million USD | -20.93% |
| 2016 FY | 1.22 Billion USD | 148.46% |
| 2016 Q4 | 275.5 Million USD | -7.55% |
| 2016 Q3 | 298 Million USD | -16.55% |
| 2016 Q2 | 357.1 Million USD | 22.7% |
| 2016 Q1 | 291.03 Million USD | 5.37% |
| 2015 Q4 | 276.2 Million USD | 93.1% |
| 2015 Q1 | 30.08 Million USD | 17.98% |
| 2015 Q2 | 42.42 Million USD | 41.04% |
| 2015 Q3 | 143.03 Million USD | 237.11% |
| 2015 FY | 491.7 Million USD | 439.74% |
| 2014 Q4 | 25.5 Million USD | 28.96% |
| 2014 Q2 | 23.54 Million USD | 5.71% |
| 2014 FY | 91.1 Million USD | -5.63% |
| 2014 Q1 | 22.27 Million USD | 7.65% |
| 2014 Q3 | 19.77 Million USD | -16.02% |
| 2013 Q2 | 23.82 Million USD | -24.08% |
| 2013 FY | 96.53 Million USD | 105.19% |
| 2013 Q4 | 20.69 Million USD | 0.25% |
| 2013 Q3 | 20.64 Million USD | -13.35% |
| 2013 Q1 | 31.37 Million USD | 92.95% |
| 2012 Q3 | 11.79 Million USD | 15.51% |
| 2012 Q2 | 10.21 Million USD | 16.34% |
| 2012 Q4 | 16.26 Million USD | 37.86% |
| 2012 Q1 | 8.77 Million USD | 51.48% |
| 2012 FY | 47.04 Million USD | 68.14% |
| 2011 Q3 | 6.8 Million USD | -32.88% |
| 2011 FY | 27.97 Million USD | -1.81% |
| 2011 Q4 | 5.79 Million USD | -14.88% |
| 2011 Q2 | 10.14 Million USD | 17.28% |
| 2011 Q1 | 8.64 Million USD | -37.8% |
| 2010 FY | 28.49 Million USD | 116.73% |
| 2010 Q2 | 7.45 Million USD | -5.89% |
| 2010 Q4 | 13.9 Million USD | 82.97% |
| 2010 Q1 | 7.92 Million USD | 13.2% |
| 2010 Q3 | 7.59 Million USD | 1.93% |
| 2009 Q2 | 2.34 Million USD | 2.0% |
| 2009 Q1 | 2.3 Million USD | 36.4% |
| 2009 FY | 13.14 Million USD | 39.27% |
| 2009 Q4 | 6.99 Million USD | 366.22% |
| 2009 Q3 | 1.5 Million USD | -36.05% |
| 2008 Q4 | 1.68 Million USD | -58.35% |
| 2008 FY | 9.44 Million USD | 1014.52% |
| 2008 Q1 | 2.82 Million USD | 233.41% |
| 2008 Q2 | 879 Thousand USD | -68.87% |
| 2008 Q3 | 4.05 Million USD | 360.75% |
| 2007 Q1 | 210 Thousand USD | 0.0% |
| 2007 Q4 | 847 Thousand USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | -100.0% |
| 2007 FY | 847 Thousand USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | -100.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | 15 Thousand USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2003 Q1 | 13 Thousand USD | 116.67% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | 13 Thousand USD | -97.69% |
| 2003 Q4 | - USD | 0.0% |
| 2002 Q1 | 333 Thousand USD | 0.0% |
| 2002 Q2 | 222 Thousand USD | -33.33% |
| 2002 FY | 562 Thousand USD | -57.84% |
| 2002 Q3 | - USD | -100.0% |
| 2002 Q4 | 6000.00 USD | 0.0% |
| 2001 Q3 | 333 Thousand USD | -0.3% |
| 2001 Q4 | 333 Thousand USD | 0.0% |
| 2001 FY | 1.33 Million USD | 54.1% |
| 2001 Q1 | 333 Thousand USD | 200.0% |
| 2001 Q2 | 334 Thousand USD | 0.3% |
| 2000 FY | 865 Thousand USD | -37.09% |
| 2000 Q1 | 344 Thousand USD | -40.17% |
| 2000 Q4 | 111 Thousand USD | 65.67% |
| 2000 Q2 | 343 Thousand USD | -0.29% |
| 2000 Q3 | 67 Thousand USD | -80.47% |
| 1999 Q3 | 300 Thousand USD | 0.0% |
| 1999 FY | 1.37 Million USD | 14.58% |
| 1999 Q4 | 575 Thousand USD | 91.67% |
| 1999 Q2 | 300 Thousand USD | 50.0% |
| 1999 Q1 | 200 Thousand USD | 0.0% |
| 1998 Q4 | 200 Thousand USD | 0.0% |
| 1998 FY | 1.2 Million USD | 1100.0% |
| 1998 Q1 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 800 Thousand USD | 700.0% |
| 1998 Q3 | 200 Thousand USD | -75.0% |
| 1997 FY | 100 Thousand USD | 0.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q4 | - USD | -100.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q4 | - USD | -100.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.415% |
| uniQure N.V. | 15.84 Million USD | -5350.325% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -2663.272% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -3119.233% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -116.222% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -9972.262% |
| bluebird bio, Inc. | 29.49 Million USD | -2827.399% |
| Blueprint Medicines Corporation | 249.38 Million USD | -246.257% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -4018.156% |
| Imunon, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | -271.741% |
| Editas Medicine, Inc. | 78.12 Million USD | -1005.302% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -579.682% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -72523.633% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 94.237% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 77.206% |
| Myriad Genetics, Inc. | 678.4 Million USD | -27.284% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 54.242% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 30.55% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -42.134% |
| Verastem, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 70.793% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 91.251% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 97.985% |
| Biogen Inc. | 9.83 Billion USD | 91.221% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 81.453% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -642.255% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -24571.286% |
| Geron Corporation | 237 Thousand USD | -364243.882% |
| Illumina, Inc. | 4.5 Billion USD | 80.828% |
| Homology Medicines, Inc. | -6.65 Million USD | 13082.935% |
| Nektar Therapeutics | 90.12 Million USD | -858.14% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 64.307% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -389.976% |
| Evolus, Inc. | 202.08 Million USD | -327.293% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 93.417% |
| FibroGen, Inc. | 147.75 Million USD | -484.422% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 87.363% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 52.77% |
| Exelixis, Inc. | 1.83 Billion USD | 52.82% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -2280.414% |
| Zoetis Inc. | 8.54 Billion USD | 89.894% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -219.104% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -9.63% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -79.009% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -4.129% |
| Insmed Incorporated | 305.2 Million USD | -182.92% |
| TG Therapeutics, Inc. | 233.66 Million USD | -269.549% |
| Incyte Corporation | 3.69 Billion USD | 76.635% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 17.708% |